AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United ...

The settlement agreement resolves all outstanding patent litigation relating to AUVELITY.

Axsome's CEO, Herriot Tabuteau, MD, expressed pride in the company's commitment to improving patient outcomes and emphasized ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ:AXSM) had ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.1 billion market cap biopharmaceutical company with impressive 91% gross profit margins, has reached a settlement agreement with Teva ...

The court also disqualified in-house patent counsel’s legal department and outside counsel because in-house patent counsel’s acquired knowledge was imputed (see Imputed Conflicts above). (837 ...

Being able to own what you create has helped make the United States ... within the Department of Commerce. That’s because Lutnick is a named inventor on hundreds of patents, including many ...

The U.S. Justice Department has sued to block tech giant HPE from acquiring Juniper Networks, the networking firm, citing ...

I tried to apply for a title over the said land, however, I was informed by the concerned government agency that a patent title was already issued ... Government agencies like the Department of ...

The US Justice Department ordered funding to be released to federal programs previously frozen by an Office of Management and Budget (OMB) memo that ordered a blanket freeze of federal funding on ...

It likewise presents a ripe opportunity for the United States ... to report a patent monetization firm, IP Edge LLC, to an ethics committee in Texas and the U.S. Department of Justice after ...